BTG2 and prostate cancer: Our results showed that Cyclins (cyclin A2, cyclin E2, cyclin F, cyclin B1), CDK2, CDC2, and other cell growth promotion genes (pescadillo, spermidine synthase, mitotin) [25-27] were down-regulated in Taxotere and/or Furtulon treated prostate cancer cells, while CDK inhibitor p21WAF1 and other growth inhibitor genes (BTG2, VDUP1, anti-proliferative B-cell translocation gene 1) [28,29] were up-regulated, suggesting that Taxotere and/or Furtulon inhibited the growth of prostate cancer cells through the arrest of cell cycle and the inhibition of cell proliferation (Figure 4).